Identifying causal variation in studies of disease associations with MHC genes

Mary Carrington Workshop on SJS/TEN March, 2015

The human MHC: epicenter of disease association as determined by GWAS





* Top Hit

HLA variation influences disease in a multifaceted manner through both acquired and innate immunity



HLA-B shows the strongest allelic associations with HIV control (relative to HLA-A and –C alleles)

HLA-B*57 protection HLA-B*27 protection HLA-B*35(Px) susceptibility

The strong allelic effects of HLA-B alleles on HIV control and the close location of HLA-B to HLA-C make it difficult to determine whether there are true effects of HLA-C variation on HIV control.

-35 promoter region SNP upstream of HLA-C associates with VL setpoint



HLA-B and HLA-C map 150Kb from one another

-35 correlates with VL and HLA-C expression levels in whites, but not blacks



The -35 SNP is unlikely to be "causal" for an effect on HIV control and for differential expression of HLA-C. What are the causal variants?

Thomas et al. Nature Genetics 2009

Variants at the unlinked loci, HLA-C and miR-148a, interact in disease pathogenesis, eliminating the possibility that their effect on HIV control is due to the neighboring HLA-B gene



HLA-B alleles are fixed for the escape variant and there is no effect of miR-148a on HLA-B expression.

Kulkarni et al, Nature, 2011 Kulkarni et al, PNAS, 2013

- The -35 SNP associated with HIV control in GWAS in whites, not blacks, and this SNP also associates with HLA-C expression in whites, not blacks (-35 SNP effect is inconsistent across populations, so this SNP is unlikely to be causal).
- Variation in the 3' UTR of HLA-C (in LD with -35 in whites) that determines miRNA regulation affects HLA-C expression levels and associates with HIV control in whites among those with HLA-C alleles that are regulated by the miRNA.
- A variant in the miRNA gene interacts with the 3'UTR variant of HLA-C in HIV control. This strengthens the "causal" effect of the HLA-C 3'UTR variant in HIV control and rules out the possibility that the association is simply marking an effect of the closely mapping HLA-B locus, as no HLA-B allele binds the miRNA.

HLA-C allotypes are expressed at differing levels on the cell surface in an allotype-dependent manner and the 3'UTR variant cannot completely account for this differential expression



Higher HLA-C expression associates with better HIV control in EA (n=2527)



Confirmation across independent cohorts, differing outcomes: Viral load in chronic infection Viral load at set point Time for progression to AIDS

224 unit change; C07 vs C06

Higher HLA-C expression associates with better HIV control in AA (n=1209)



Significant independent effects with p<0.001

Confirmation across populations: HLA allele frequencies and linkage disequilibrium between HLA loci differ between AA and EA.

Functional data are invaluable for attributing causation to a genetic association: The frequency of HLA-C restricted CTL responses to HIV peptides correlates positively with the level of HLA-C expression



- Measurement of HLA-C expression levels across alleles allowed a direct test for an association between HLA-C expression levels and HIV control, rather than involving the -35 SNP proxy or a variant that accounts for only part of the differential expression (3'UTR).
- The effect of HLA-C expression levels was consistent in black and white cohorts, and across different HIV outcomes.
- Functional data explain/support an effect of HLA-C expression on HIV control through enhanced CTL activity among those with high expression levels of HLA-C.

Carrington lab **Richard Apps** Arman Bashirova Fuh-Mei Duh Smita Kulkarni Pat Martin **Veron Ramsuran Nicolas Vince** Gao Xiaojiang Yuko Yuki

<u>Ragon Institute</u> Florencia Pereyra Bruce Walker

<u>Univ. Lausanne</u> Paul McLaren Jacques Fellay

<u>Microsoft</u> David Heckerman Jonathan Carlson

<u>CIP Core</u> Ying Qi Colm O'hUigin <u>Simon Fraser Univ.</u> Zabrina Brumme

<u>Oxford Univ.</u> Philip Goulder

HIV Cohorts

MACS Steven Wolinsky SHCS Amalio Telenti SCOPE Steve Deeks, Peter Hunt IHCC Bruce Walker MHCS Jim Goedert USMNHS Amy Wientrob ALIVE Greg Kirk SFCCC Susan Buchbinder



U.S. DEPARTMENT OF HEALTH AND Human services

National Institutes of Health